Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 14/20 | 0.41 |
| ▸ | PLK3 | Q9H4B4 | 9/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.37 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.37 |
| ▸ | NEK2 | P51955 | 3/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.35 |
| ▸ | PIM1 | P11309 | 2/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.35 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2977915 | 0.94 | AKR1B1 (0.41) | PLK1PLK3TP53RXFP1RAB9A | |
| SCHEMBL2977918 | 0.94 | AKR1B1 (0.41) | PLK1PLK3TP53RXFP1RAB9A | |
| SCHEMBL4560751 | 0.91 | PLK1 (0.41) | PLK1PLK3TP53RXFP1RAB9A | |
| SCHEMBL2982288 | 0.91 | PLK1 (0.41) | PLK1PLK3TP53RXFP1RAB9A | |
| SCHEMBL14568212 | 0.90 | PLK1 (0.39) | PLK1PLK3TP53RXFP1RAB9A | |
| SCHEMBL13592940 | 0.90 | PLK1 (0.39) | PLK1PLK3TP53RXFP1RAB9A | |
| SCHEMBL5141224 | 0.85 | PLK1 (0.37) | PLK1PLK3RAB9ACYP3A4CYP2C9 | |
| SCHEMBL2990377 | 0.85 | PLK1 (0.37) | PLK1PLK3RAB9ACYP3A4CYP2C9 | |
| SCHEMBL2973849 | 0.85 | AKR1C3 (0.41) | PLK1PLK3RAB9AAKR1B10AKR1B1 | |
| SCHEMBL2973853 | 0.85 | AKR1C3 (0.41) | PLK1PLK3RAB9AAKR1B10AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786127-B2 | Benzimidazole thiophene compounds | Glaxo SmithKline LLC (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786127-B2 | Benzimidazole thiophene compounds | Glaxo SmithKline LLC (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786127-B2 | Benzimidazole thiophene compounds | Glaxo SmithKline LLC (US) | 2010-08-31 | — | — | US | disclosed |
| WO-2009154645-A1 | METHODS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM TUMORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009154645-A1 | METHODS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM TUMORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-23 | — | — | WO | disclosed |
| EP-1937671-B1 | BENZIMIDAZOLE THIOPHENE COMPOUNDS AS PLK INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-12-16 | — | — | EP | disclosed |
| EP-1937671-B1 | BENZIMIDAZOLE THIOPHENE COMPOUNDS AS PLK INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-12-16 | — | — | EP | disclosed |
| US-7595330-B2 | Benzimidazole thiophene compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595330-B2 | Benzimidazole thiophene compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595330-B2 | Benzimidazole thiophene compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-20090005398-A1 | Methods For The Treatment of Central Nervous System Tumors | SMITHKLINE BEECHAM CORPORATION | 2009-01-01 | — | — | US | disclosed |
| US-20080214567-A1 | Benzimidazole Thiophene Compounds | GLAXOSMITHKLINE LLC | 2008-09-04 | — | — | US | disclosed |
| US-20080214567-A1 | Benzimidazole Thiophene Compounds | GLAXOSMITHKLINE LLC | 2008-09-04 | — | — | US | disclosed |
| US-20080214567-A1 | Benzimidazole Thiophene Compounds | GLAXOSMITHKLINE LLC | 2008-09-04 | — | — | US | disclosed |
| EP-1937671-A2 | BENZIMIDAZOLE THIOPHENE COMPOUNDS AS PLK INHIBITORS | SmithKline Beecham Corporation (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20070270437-A1 | Benzimidazole Thiophene Compounds | CHEUNG MUI | 2007-11-22 | — | — | US | disclosed |
| US-20070270437-A1 | Benzimidazole Thiophene Compounds | CHEUNG MUI | 2007-11-22 | — | — | US | disclosed |
| US-20070270437-A1 | Benzimidazole Thiophene Compounds | CHEUNG MUI | 2007-11-22 | — | — | US | disclosed |
| WO-2007030361-A2 | BENZIMIDAZOLE THIOPHENE COMPOUNDS AS PLK INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007030361-A2 | BENZIMIDAZOLE THIOPHENE COMPOUNDS AS PLK INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005398-A1 | Methods For The Treatment of Central Nervous System Tumors | TUBB3, TUBB6, TUBB | PLK1 424/4885PLK3 1271/4885TP53 54/4885 |
| US-20080214567-A1 | Benzimidazole Thiophene Compounds | ABCB1, ABCG2, CYP3A5 | PLK1 344/4885PLK3 934/4885TP53 1145/4885 |
| US-20070270437-A1 | Benzimidazole Thiophene Compounds | ABCB1, CYP3A5, ABCG2 | PLK1 458/4885PLK3 1235/4885TP53 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.